Navigation Links
Regulus Demonstrates Initial Progress in microRNA Biomarkers MS Collaboration and Receives Milestone Payment from Biogen Idec
Date:11/20/2013

therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Study demonstrates cells can acquire new functions through transcriptional regulatory network
2. New study demonstrates the role of urban greenery in CO2 exchange
3. WALTHAM® demonstrates commitment to scientific dialogue and exchange at international human animal interaction conference
4. Published clinical trial demonstrates efficacy of Sea-Band® for migraine-related nausea
5. University of Toronto study demonstrates impact of adversity on early life development
6. UT Arlington physics team demonstrates new power generation technique
7. First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment
8. Genetic study of house dust mites demonstrates reversible evolution
9. Rotavirus vaccine developed in India demonstrates strong efficacy
10. Fingerprint Cards (FPC) Demonstrates Fingerprint Biometric Touch Sensor for Microsoft Windows 8.1
11. Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... University Medical Center, Chicago, and Ceregene Inc., San Diego, ... and stop the anatomic, cellular changes that occur in ... is the first study to demonstrate that, using this ... mice with this treatment. , Results of the ...
... The Hospital for Sick Children (SickKids) and the University of ... can create neural cell types that can be transplanted into ... reported in the June 14, 2006 issue of The Journal ... of cells can be made from these stem cells (called ...
... that go on to form the face, skull and ... is determined much earlier in development than previously thought, ... according to a recent study published in the journal ... with three different technologies -- immunostaining of proteins, in ...
Cached Biology News:Gene therapy injected into the brains' of mice with Huntington's disease 2Gene therapy injected into the brains' of mice with Huntington's disease 3Gene therapy injected into the brains' of mice with Huntington's disease 4Stem cells found in adult skin can be transplanted and function in mouse models of disease 2Making a face: A new and earlier marker of neural crest development 2
(Date:7/25/2015)... ... July 25, 2015 , ... Technology ... It precisely checks and adjusts the surface temperature of the measuring prism. This ... pharmaceutical industry, data traceability and documentation are key requirements. It is likely that ...
(Date:7/24/2015)... Diego, CA (PRWEB) , ... July 24, 2015 , ... ... & Referral Center in support of stem cell therapy training and clinical opportunities. , ... this new opportunity to veterinarians in the San Diego area. Stem cell therapy is ...
(Date:7/24/2015)...  Champions Oncology (OTC-BB: CSBR), a company engaged in ... personalize the development and use of oncology drugs, today ... for the fourth quarter and fiscal year quarter ended ... market open. The company will host a ... 9:00 a.m. EDT (6:00 a.m. PDT). To participate in ...
(Date:7/24/2015)... , July 24, 2015 Origin Agritech Limited (NASDAQ ... crop seeds in China , today announced ... fiscal year 2015 ended June 30, 2015, before the market ... will host a teleconference on August 5th, 2015, at 9:00 ... time to discuss the results. To participate in the call, ...
Breaking Biology Technology:It’s T-Time for Refractometers: On-site Temperature Check Now Available 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3
... US - A team of Bioengineers in the United ... its ability to produce ethanol. The research, published in ... metabolic engineering can be combined for strain improvement, a ... focused their research on Zymomonas mobilis, a bacterium noted ...
... NEW YORK, Dec. 10, 2010 Ramius V&O Acquisition ... announced that it has sent a letter to the ... CYPB ) outlining its willingness to acquire all ... for $5.50 per share.  The offer is conditioned upon ...
... new hand-held medical device will help UK athletes reach ... sporting competitions. UK Sport, the UK,s high performance sports ... organisation to use cutting edge technology developed by Argento ... athletes will be able to monitor various proteins which ...
Cached Biology Technology:Bioengineers develop bacterial strain to increase ethanol biofuel production 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6Medical science helps UK athletes reach peak performance 2Medical science helps UK athletes reach peak performance 3
NATIVE RAT OSTEOCALCIN...
... W x H): 17 3/4" x ... 12 slidesTime: Programmable 0 - 100 hoursControl: ... hybridization steps 40 user programmable protocols 3 ... temperature) Rapid temperature ramp-up from 37 - ...
Defender against cell death 1...
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
Biology Products: